Literature DB >> 7667204

Without extrapolation, Cmax/AUC is an effective metric in investigations of bioequivalence.

L Tothfalusi1, L Endrenyi.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7667204     DOI： 10.1023/a:1016237826520

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  11 in total

1.  Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.

Authors:  R L Williams; W Adams; M L Chen; D Hare; A Hussain; L Lesko; R Patnaik; V Shah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Average parameters as a trend to reduce the residual variability in bioequivalence trials.

Authors:  P Fagiolino; M Vazquez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

6.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

7.  The duration of measuring partial AUCs for the assessment of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; A H Balch; M L Chen
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

8.  Sensitive and specific determination of the equivalence of absorption rates.

Authors:  L Endrenyi; P Al-Shaikh
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

9.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.

Authors:  Laszlo Tothfalusi; Szilvia Speidl; Laszlo Endrenyi
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

10.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.